Recent News

• 06.12.2025 - Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
• 06.12.2025 - Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
• 06.12.2025 - Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
• 06.12.2025 - Celldex EAACI 76 Week CSU Conference Call & Webcast
• 06.12.2025 - Celldex EAACI 76 Week CSU Conference Call & Webcast
• 06.11.2025 - Richard Law
• 06.11.2025 - Richard Law
• 06.11.2025 - David Lebowitz
• 06.11.2025 - David Lebowitz
• 06.10.2025 - Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress

Recent Filings

• 06.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2025 - 4 Statement of changes in beneficial ownership of securities